Security key
87184Q206
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (SYRS)
CUSIP: 87184Q206
Q2 2024 13F Holders as of 30 Jun 2024
- Security type / class
- Equity / Common Stock, $0.001 par value per share
- Total 13F shares
- 20,382,905
- Total 13F value
- $105,175,826
- Share change
- -532,680
- Put/Call ratio
- 15%
- SEC-reported price per share
- $5.16
- Number of holders
- 70
- Value change
- -$2,839,834
- Number of buys
- 30
- Number of sells
- 27
- Shares outstanding
- 27,196,692
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2024
Institutions
70
Top holders
10
SYRS full security history
Ownership snapshot
Full 13F holder table
Syros Pharmaceuticals, Inc. SEC filings
Syros Pharmaceuticals, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of SYRS - Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Bain Capital Life Science...
Disclosed value leader
Bain Capital Life Science...
Comparable rows
15/15
Latest evidence
31 Mar 2024
13F
Lead comparable stake: 10%
Showing 1-6 of 15 holder rows.
Quick read
Bain Capital Life Sciences Investors, LLC leads the comparable SEC ownership view at 10%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Bain Capital Life Sciences Investors, LLC's linked filing trail.
Comparable ownership
Top 5
Bain Capital Life Sciences Invest...
10%
Artal Group S.A.
9.2%
ADAGE CAPITAL PARTNERS GP, L.L.C.
7.6%
Samsara BioCapital, LLC
6.6%
Avidity Partners Management LP
6.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC |
13F
Company
|
10%
|
$14,711,473
2,749,808 shares
|
— | 31 Mar 2024 |
| Artal Group S.A. |
13F
Company
|
9.2%
|
$13,401,820
2,505,013 shares
|
— | 31 Mar 2024 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
Company
|
7.6%
|
$11,084,740
2,071,914 shares
|
— | 31 Mar 2024 |
| Samsara BioCapital, LLC |
13F
Company
|
6.6%
|
$9,557,384
1,786,427 shares
|
— | 31 Mar 2024 |
| Avidity Partners Management LP |
13F
Company
|
6.2%
|
$8,953,428
1,673,538 shares
|
— | 31 Mar 2024 |
| Point72 Asset Management, L.P. |
13F
Company
|
5.4%
|
$7,873,975
1,471,771 shares
|
— | 31 Mar 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
70
Shares
20,382,905
Rows available
70
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
74
Q2 2024 holders
70
Holder diff
-4
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 value | Q2 2024 value | Value change | Value Chg % |
|---|